This Pregnancy Registry has been established to learn about pregnancy outcomes and the health of women who have taken Herceptin, Perjeta, or Kadcyla within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy. These drugs are not approved for use during pregnancy and women of childbearing potential should be advised to avoid becoming pregnant or nursing while taking Herceptin, Perjeta, or Kadcyla.
The MotHER Pregnancy Registry is a U.S. - based, prospective, observational study of women with HER2+ breast cancer who were treated with a regimen that contains Herceptin, Perjeta, or Kadcyla during pregnancy or within six months prior to conception. Women who are interested in enrolling may contact the Registry directly by calling 1-800-690-6720.
The primary objective of this Pregnancy Registry is to describe adverse pregnancy complications (e.g., oligohydramnios, delayed renal development), pregnancy outcomes (i.e., live births, stillbirths, and abortions), fetal/infant outcomes (e.g., major malformations, deformations, and disruptions), and fetal or infant functional deficits among women with breast cancer treated with trastuzumab (either in combination with chemotherapies, or as a single agent), the subset of women treated with pertuzumab plus trastuzumab, or patients treated with ado-trastuzumab emtansine during pregnancy or within 6 months prior to conception.
Due to the observational nature of this Registry, participation in the Registry will not influence or interfere with the treatment plan recommended by the patient's healthcare provider.
If you are interested in additional information, click on contact us for the Registry Coordinating Center.
PERJETA® (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Kadcyla® (ado-trastuzumab emtansine), injection for intravenous use, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
The success of The MotHER Pregnancy Registry depends on the continued participation of healthcare providers and pregnant women who have been exposed to Genentech manufactured Herceptin, Perjeta, or Kadcyla. Participation from patients and healthcare providers is greatly appreciated.